Biodelivery Sciences International Inc (NASDAQ:BDSI) Reports Increase in Sellers; Strong Momentum for Short Players

May 17, 2018 - By James Guidry

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Logo

Investors sentiment increased to 2.13 in Q4 2017. Its up 0.46, from 1.67 in 2017Q3. It is positive, as 4 investors sold BioDelivery Sciences International, Inc. shares while 11 reduced holdings. 15 funds opened positions while 17 raised stakes. 22.65 million shares or 11.32% more from 20.34 million shares in 2017Q3 were reported.
Millennium Management Limited Liability has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Bailard stated it has 558,000 shares. 1,000 are held by Citigroup. Cutter Brokerage accumulated 42,010 shares. Goldman Sachs Inc holds 0% or 75,593 shares in its portfolio. Deutsche Bancshares Ag reported 0% stake. Sigma Planning reported 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Virtu Finance Ltd Limited Liability Company has invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Fny Managed Accounts Lc stated it has 500 shares or 0% of all its holdings. Bancorp Of Mellon Corporation owns 44,668 shares for 0% of their portfolio. Archford Capital Strategies Limited Co has invested 0.04% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Morgan Stanley holds 138,835 shares. Barclays Public Limited Com owns 72,386 shares. Broadfin Capital Limited Liability, a New York-based fund reported 4.63M shares. Ameriprise reported 1.31M shares.

Since January 2, 2018, it had 0 insider purchases, and 4 sales for $2.52 million activity. On Tuesday, April 3 De Paolantonio Ernest Robert sold $134,013 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) or 64,155 shares. On Wednesday, March 7 ODONNELL FRANCIS E JR sold $243,223 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) or 113,876 shares.

The stock of Biodelivery Sciences International Inc (NASDAQ:BDSI) registered an increase of 3.19% in short interest. BDSI’s total short interest was 2.96M shares in May as published by FINRA. Its up 3.19% from 2.87M shares, reported previously. With 136,500 shares average volume, it will take short sellers 22 days to cover their BDSI’s short positions. The short interest to Biodelivery Sciences International Inc’s float is 6.76%.

The stock increased 21.79% or $0.42 during the last trading session, reaching $2.38. About 1.51M shares traded or 324.74% up from the average. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 10.53% since May 17, 2017 and is uptrending. It has underperformed by 1.02% the S&P500.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $140.77 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 26.39 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 3 analysts covering BioDelivery (NASDAQ:BDSI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery had 7 analyst reports since November 27, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Friday, April 13 by H.C. Wainwright. H.C. Wainwright maintained the shares of BDSI in report on Monday, May 7 with “Buy” rating. Cantor Fitzgerald maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Thursday, March 15 with “Buy” rating. As per Monday, March 19, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Tuesday, February 6. H.C. Wainwright has “Buy” rating and $5.0 target. H.C. Wainwright maintained the shares of BDSI in report on Monday, November 27 with “Buy” rating.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Streetinsider.com which released: “BioDelivery Sciences (BDSI) Reports Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business” on May 17, 2018, also Nasdaq.com with their article: “BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on …” published on April 30, 2018, Globenewswire.com published: “BioDelivery Sciences Appoints Herm Cukier as Chief Executive Officer” on May 07, 2018. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Streetinsider.com and their article: “Pre-Open Movers 05/17: (WWE) (LOXO) (NTES) Higher; (JNCE) (JCP) (ACXM) Lower (more…)” published on May 17, 2018 as well as Bizjournals.com‘s news article titled: “Raleigh pharma ushers in new CEO from Allergan” with publication date: May 08, 2018.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: